ABSTRACT
Itraconazole is as an anti-fungal agent with the ability to inhibit the Hedgehog signalling pathway, which makes it a candidate drug that can be repurposed for the treatment of basal cell carcinomas (BCCs). We present a case of metastatic BCC, treated with oral itraconazole 100 mg twice daily, that resulted in sustained partial regression of metastatic pulmonary nodules. A systematic review on the clinical outcomes of BCCs treated with itraconazole highlights that current evidence for its clinical application remains limited and that this is the first case report where itraconazole monotherapy has achieved favourable response in metastatic BCC.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Itraconazole/therapeutic use , Skin Neoplasms/drug therapy , Administration, Oral , Carcinoma, Basal Cell/pathology , Humans , Signal Transduction/drug effects , Skin Neoplasms/pathology , Treatment OutcomeABSTRACT
A 10-year-old boy was diagnosed with a thick neurotropic melanoma of the lip in 2002. He is alive and well without evidence of disease recurrence 10 years later. We applied modern pathologic techniques to this lesion to highlight recent advances in melanoma diagnostics.